"As-required" combination therapy with inhaled corticosteroids and long-acting beta-2 agonists for asthma: Current evidence and recommendations

New Zealand Medical Journal

Volumn 121, Issue 1285, 2008, Pages

  Taylor, D Robin ^a,b   Jayaram, Lata ^a   Asher, M Innes ^a   Epton, Michael J ^a  

^a Thoracic Society of Australia and New Zealand (New Zealand Branch)   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE PLUS SALBUTAMOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FENOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IMMUNOGLOBULIN E ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; PLACEBO; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; TERBUTALINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ASTHMA; AUSTRALIA AND NEW ZEALAND; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DISEASE EXACERBATION; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; HYPOTHESIS; INHALER; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; PATIENT EDUCATION; PRACTICE GUIDELINE; REVIEW; SINGLE DRUG DOSE; SYSTEMIC DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ASTHMA; DRUG THERAPY, COMBINATION; HUMANS; PATIENT EDUCATION AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 56649094126     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994;344(8917):219-24.
2. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997;337(20):1405-11.
3. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1392-7.
4. Hancox RJ. Interactions between corticosteroids and beta2-agonists. Clin Rev Allergy Immunol. 2006;31(2-3):231-46.
5. Barnes PJ. A single inhaler for asthma? Am J Respir Crit Care Med. 2005;171(2):95-6.
6. Goldsmith DR, Keating GM. Budesonide/formoterol: A review of its use in asthma. Drugs 2004;64(14):1597-618.
7. Edwards SJ, Gruffydd-Jones K, Ryan DP. Systematic review and meta-analysis of budesonide/formoterol in a single inhaler. Curr Med Res Opin. 2007;23(8):1809-20.
8. Bosley CM, Parry DT, Cochrane GM. Patient compliance with inhaled medication: Does combining beta-agonists with corticosteroids improve compliance? Eur Respir J. 1994;7(3):504-9.
9. Rand CS, Wise RA, Nides M, et al. Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis. 1992;146(6):1559-64.
10. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005;115(2):233-42.
11. Haldar P, Pavord ID. Noneosinophilic asthma: A distinct clinical and pathologic phenotype. J Allergy Clin Immunol. 2007;119(5):1043-52; quiz 1053-4.
12. Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: Identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002;57(10):875-9.
13. Sont JK, Han J, van Krieken JM, et al. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax. 1996;51(5):496-502.
14. Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007;356(20):2040-52.
15. Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: A randomised controlled, double-blind study. Lancet. 2006;368(9537):744-53.
16. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171(2):129-36. Epub 2004 Oct 22.
17. Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: A randomized, double-blind trial. Chest. 2006;129(2):246-56.
18. Bisgaard H. Effect of long-acting beta2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol 2003;36(5):391-8.
19. Bisgaard H, Le Roux P, Bjamer D, et al. Budesonide/formoterol maintenance plus reliever therapy: A new strategy in pediatric asthma. Chest. 2006;130(6):1733-43.
20. Tattersfield AE, Lofdahl CG, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: A randomised trial. Lancet. 2001;357(9252):257-61.
21. Taylor DR, Pijnenburg MW, Smith AD, De Jongste JC. Exhaled nitric oxide measurements: Clinical application and interpretation. Thorax. 2006;61(9):817-27.
22. Leone FT, Fish JE, Szefler SJ, West SL. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: Collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. Chest. 2003;124(6):2329-40.
23. Sears MR, Boulet LP, Laviolette M, et al. Budesonide/formoterol maintenance and reliever therapy: Impact on airway inflammation in asthma. Eur Respir J 2008.
24. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15-26.
25. Aldridge RE, Hancox RJ, Robin Taylor D, et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med. 2000;161(5):1459-64.
26. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990;336(8728):1391-6.
27. Bruggenjurgen B, Selim D, Kardos P, et al. Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma. Pharmacoeconomics 2005;23(7):723-31.
28. Vogelmeier C, D'Urzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option? Eur Respir J. 2005;26(5):819-28.
29. Miller E, Sears MR, McIvor A, Liovas A. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Can Respir J. 2007;14(5):269-75.
30. Price D, Wiren A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy. 2007;62(10):1189-98.